Eli Lilly added $7.4 billion of revenue in three months, more than the $5.2 billion it generated outside the U.S. in the same period. Sales rose from $15.6 billion to $23.0 billion versus the comparable period a year earlier, a growth rate of 47.7%.

The profit line was less cooperative. Net income rose 25.3% to $7.1 billion, while net margin fell from 36.4% to 30.9%. Lilly sold much more, but kept a smaller share of each dollar.

Management points first to Zepbound. The drug’s U.S. revenue rose 44% during the three months, with strong demand doing the lifting and lower realized prices taking some of it back.

"Revenue of Zepbound increased 44 percent and 58 percent in the U.S. during the three and six months ended June 30, 2026, respectively, primarily driven by strong demand, partially offset by lower realized prices, including previously announced reductions in cash-pay prices."

Lilly, 10-Q filed Aug. 5, 2026

That sentence contains the filing’s central trade-off: volume is expanding, but price is not moving in the same direction. Lilly also said U.S. volume growth was primarily driven by Zepbound and Mounjaro, making the product engine fairly easy to identify.

The company’s own explanation for earnings is similarly two-sided:

"Net income and earnings per share for the three months ended June 30, 2026 increased primarily due to higher gross margin, partially offset by higher acquired IPR&D charges, asset impairment, restructuring, and other special charges, and marketing, selling, and administrative expenses."

Lilly, 10-Q filed Aug. 5, 2026

In plain English, better gross profit powered the increase, but a larger expense bill absorbed part of the sales growth. Diluted EPS rose 26.2% to 7.94, helped slightly by a 0.7% decline in diluted shares, but the earnings gain still lagged the revenue surge.

The balance sheet adds another piece without supplying a cause. Cash rose 165.1% to $8.9 billion, while inventory increased 52.5% and accounts receivable climbed 41.7%. Inventory therefore grew faster than revenue, and the company disclosed higher inventory intensity. Those figures describe where the business stood on June 30; they do not, by themselves, explain why.

The annual record shows why the latest period matters. Revenue reached $65.2 billion in 2025 after rising 44.7%, while annual net margin reached 31.7%. Lilly has built a much larger sales base quickly, while the latest three-month margin was below that annual level. The filing also cites lower realized prices and listed charges in its discussion of results.

At 48.7 times earnings, the valuation is notable alongside the distinction between volume growth and pricing power. That is not a forecast, just the arithmetic of a business whose newest sales are arriving with a narrower margin.

Lilly’s next quarterly report should contain one useful comparison: whether realized prices and inventory intensity move closer together or remain on opposite tracks. For now, the filing leaves a clean summary: more medicine sold, less margin kept.